Advertisement
ALLO vs EDIT
Which Stock Would AI Choose? Allogene Therapeutics (ALLO) vs. Editas Medicine (EDIT) Stock Comparison
Key Takeaways
- Both ALLO and EDIT are clinical-stage biotechnology companies with no approved products, making their stock narratives driven almost entirely by pipeline data and cash runway.
- Allogene is advancing "off-the-shelf" CAR T (chimeric antigen receptor T-cell) therapies, led by cema-cel in a pivotal Phase 2 lymphoma study, while Editas is pivoting toward in vivo (inside-the-body) gene editing led by EDIT-401 for high cholesterol.
- Allogene reported a strong interim MRD (minimal residual disease) negativity signal of 58.3% versus 16.7% for observation, while Editas secured Australian clearance to begin its first human trial of EDIT-401.
- Both stocks have rallied year-to-date but pulled back sharply in recent weeks, reflecting the volatile, catalyst-driven nature of early-stage biotech equities.
- Allogene's cash runway extends into 2029, whereas Editas projects funding into the second half of 2028, giving Allogene a somewhat longer financial cushion.
- For more detail on key developments and intraday activity, explore ALLO Major News and ALLO Today's Price Move, as well as EDIT Major News and EDIT Today's Price Move.
- Interested in how automated systems are positioning across these and other names? Explore Trending AI Robots for a curated view of top-performing strategies.
Introduction
Allogene Therapeutics (ALLO) and Editas Medicine (EDIT) sit at the intersection of two of biotechnology's most closely watched frontiers: engineered cell therapy and CRISPR (clustered regularly interspaced short palindromic repeats) gene editing. Neither company yet generates meaningful product revenue, so their valuations hinge on clinical catalysts, trial readouts, and balance-sheet durability. This comparison is most relevant to growth-oriented and event-driven investors who track high-risk, high-reward biotech names and want to understand how relative performance, pipeline positioning, and market sentiment differ between two development-stage leaders.
ALLO Overview and Recent Performance
Allogene Therapeutics develops allogeneic, or "off-the-shelf," CAR T-cell therapies for cancer and autoimmune disease. Unlike autologous treatments that use a patient's own cells, Allogene's platform uses healthy donor cells engineered for broader availability and faster treatment. Its lead program, cema-cel, is in the pivotal Phase 2 ALPHA3 study in large B-cell lymphoma, with an interim futility analysis showing 58.3% MRD negativity at day 45 versus 16.7% for observation. The company also advanced ALLO-329 into a Phase 1 study across autoimmune conditions. After a public offering raised roughly $200 million, Allogene reported approximately $423.6 million in cash and investments as of mid-2026, supporting a runway into 2029. Despite strong year-to-date gains, shares pulled back notably in recent weeks, reflecting profit-taking and sector-wide volatility following a period of positive clinical momentum.
EDIT Overview and Recent Performance
Editas Medicine is a pioneer in CRISPR-based gene editing. Following the late-2024 discontinuation of its reni-cel program and a roughly 65% workforce reduction, the company refocused on in vivo editing. Its lead candidate, EDIT-401, is a one-time therapy designed to edit the LDLR gene and durably lower LDL (low-density lipoprotein) cholesterol in patients with heterozygous familial hypercholesterolemia, an inherited condition linked to elevated cardiovascular risk. In recent weeks, Editas received Australian regulatory clearance to begin its Phase 1/2 Strive trial, its first human study of EDIT-401, supported by preclinical data showing roughly 90% reductions in atherogenic lipoproteins. The company reported approximately $211.6 million in cash and investments, with a runway into the second half of 2028. Shares climbed year-to-date before easing in recent trading, with analysts highlighting 2027 as a potential inflection point.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI trading bots. While Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, only those best suited to current market conditions earn a place in this featured section. These bots span a wide range of trading styles, strategies, timeframes, performance statistics, and ticker sets, with individual robots demonstrating varying win rates, trade frequencies, and risk profiles. For investors comparing volatile names like ALLO and EDIT, reviewing which strategies are currently trending can offer useful context on prevailing market conditions. Explore the Trending AI Robots page to see which approaches are gaining traction now.
Head-to-Head Comparison
The two companies differ sharply in therapeutic focus and maturity. Allogene targets oncology and autoimmune disease through cell therapy, with a lead program already in a pivotal study and multiple near-term data readouts on the horizon. Editas is effectively at a preclinical-to-early-clinical transition, betting on a single in vivo program in cardiovascular disease. In terms of growth drivers, Allogene's value rests on translating promising MRD data into a durable event-free survival signal, while Editas's hinges on early human safety and efficacy results for EDIT-401. Risk profiles also diverge: Allogene carries clinical and manufacturing-scale risks across a broader pipeline but holds a longer cash runway, while Editas faces concentrated single-asset risk and earlier-stage uncertainty, with a shorter runway. Sector exposure overlaps in biotechnology, yet momentum has favored whichever company delivers the most recent catalyst, underscoring the event-driven nature of both names.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet durability, and the maturity of clinical catalysts, Tickeron's AI would likely view ALLO as holding a modest relative edge in the current environment. A later-stage pivotal program, a longer cash runway, and a broader pipeline of near-term readouts provide a comparatively steadier catalyst path. EDIT carries meaningful upside potential tied to its first-in-human data, but that potential is more concentrated and earlier-stage, introducing greater variability. This assessment is probabilistic rather than definitive, reflecting the inherent uncertainty of clinical-stage investing rather than a recommendation to buy or sell either security.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and EDIT is a StrongBuy.
ALLO in -15.09% downward trend, sliding for three consecutive days on November 11, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALLO declined for three days, in 283 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLO as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ALLO turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
The Aroon Indicator for ALLO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in 185 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.824) is normal, around the industry mean (3.498). P/E Ratio (-1.576) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Aroon Indicator for EDIT shows an upward move is likely
EDIT's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 154 similar instances where the Aroon Indicator showed a similar pattern. In 128 of the 154 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ALLO | EDIT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 99 | |
PRICE GROWTH RATING 1..100 | 88 | 71 | |
P/E GROWTH RATING 1..100 | 12 | 30 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALLO's Valuation (48) in the Biotechnology industry is in the same range as EDIT (53). This means that ALLO’s stock grew similarly to EDIT’s over the last 12 months.
ALLO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that ALLO’s stock grew similarly to EDIT’s over the last 12 months.
ALLO's SMR Rating (97) in the Biotechnology industry is in the same range as EDIT (99). This means that ALLO’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's Price Growth Rating (71) in the Biotechnology industry is in the same range as ALLO (88). This means that EDIT’s stock grew similarly to ALLO’s over the last 12 months.
ALLO's P/E Growth Rating (12) in the Biotechnology industry is in the same range as EDIT (30). This means that ALLO’s stock grew similarly to EDIT’s over the last 12 months.
| ALLO | EDIT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | N/A |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| Advances ODDS (%) | 9 days ago 81% | 4 days ago 80% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALLO’s FA Score shows that 1 FA rating(s) are green while EDIT’s FA Score has 1 green FA rating(s).
- ALLO’s FA Score: 1 green, 4 red.
- EDIT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALLO’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).
- ALLO’s TA Score: 4 bullish, 4 bearish.
- EDIT’s TA Score: 3 bullish, 6 bearish.
Price Growth
ALLO (@Biotechnology) experienced а -24.36% price change this week, while EDIT (@Biotechnology) price change was -12.50% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
Reported Earning Dates
ALLO is expected to report earnings on Mar 18, 2027.
EDIT is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALLO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To ALLO | 1D Price Change % | ||
|---|---|---|---|---|
| ALLO | 100% | -3.41% | ||
| EDIT - ALLO | 49% Loosely correlated | -4.99% | ||
| AXON - ALLO | 44% Loosely correlated | +4.26% | ||
| RCKT - ALLO | 43% Loosely correlated | +1.22% | ||
| ARRY - ALLO | 43% Loosely correlated | +9.94% | ||
| FDMT - ALLO | 43% Loosely correlated | +4.25% | ||
More | ||||
EDIT and
Correlation & Price change
A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To EDIT | 1D Price Change % | ||
|---|---|---|---|---|
| EDIT | 100% | -4.99% | ||
| BEAM - EDIT | 67% Closely correlated | +2.62% | ||
| CRSP - EDIT | 63% Loosely correlated | +1.33% | ||
| SLDB - EDIT | 62% Loosely correlated | +6.00% | ||
| PRME - EDIT | 61% Loosely correlated | +10.26% | ||
| VYGR - EDIT | 61% Loosely correlated | -3.56% | ||
More | ||||